Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing

HATFIELD, Pa., Feb. 10, 2014 /PRNewswire/ -- Genisphere LLC reported today it has been granted a US patent for a novel strand-specific library preparation method for next generation sequencing based on its proven RNA amplification technology. The new patented process enables amplification and library preparation from clinically relevant RNA samples, adapts easily to a variety of sequencing instruments and systems, and reduces the time required for sample preparation by eliminating labor intensive steps.

Genisphere's RNA amplification technology employs a robust whole transcriptome amplification process that has been successfully integrated into several assay systems.  In 2008, Genisphere's amplification technology was incorporated into the Pathwork Diagnostics Tissue of Origin Test (now offered by Response Genetics), which was cleared by the FDA in 2010. In 2011, the latest version of the company's amplification technology, trademarked Sensation®, was licensed to Affymetrix for microarray applications.

"Genisphere's technology for whole transcriptome amplification is a dynamic commonality among our diverse corporate initiatives, which include targeted therapeutics, clinical diagnostics, and life science", said Bob Getts, Genisphere's Chief Science Officer. "We are pleased to offer these methods to our collaborators and partners who are interested in broadening their translational research initiatives in the areas of new drug discovery, diagnostic assay development, and moving next generation sequencing from the research lab to the clinic. We also see this as an excellent tool to complement our 3DNA nanoparticle technology used for targeted drug delivery since it will help to uncover those molecules that will be ideal targets for companion diagnostics based on next generation sequencing."

About Genisphere
Genisphere LLC is a nanotechnology company providing innovative tools for targeted drug delivery, clinical diagnostics and life science research based on the company's 3DNA nanoparticle platform. Genisphere's unique, IP-protected, 3DNA^® technology has broad applicability to improve the sensitivity in immunoassay and nucleic acid detection platforms, as well as to deliver therapeutics in a highly specific manner. Genisphere has successfully out-licensed several reagent kits to the research market, and provides customized products to improve the limit of detection of high-sensitivity lateral flow point-of-care tests, enabling their commercialization. Genisphere's diagnostic partners have a competitive advantage due to 3DNA's ability to improve their test's sensitivity, with minimal additional costs and no alterations to end-user protocols. For targeted therapeutics, Genisphere provides a fully customizable
all-DNA drug delivery platform. Genisphere's robust nanocarrier delivers small drug, RNAi and gene construct therapeutics with greatly improved efficacy and reduced toxicity. The company is continuing to seek partnerships with biotechnology and pharmaceutical companies that could benefit from Genisphere's platform technology. For more information, please visit http://genisphere.com

For more information contact:

Bob Getts
Genisphere  
215-996-3027
Email

Read more news on Genisphere.

SOURCE Genisphere

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED